Clinical Trial Update: A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 study of ARQ 501 in patients with head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ARQ 501

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 2 | Status: COMPLETED